Statera Biopharma (STAB) 10-Q 12 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	CBLI
Entity Registrant Name	CLEVELAND BIOLABS INC
Entity Central Index Key	1,318,641
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,729,123

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 3,190,121	$ 3,103,969
Short-term investments	450,256
Accounts receivable	133,476	267,199
Receivable for divestiture of Incuron, LLC	1,000,000
Other current assets	215,699	174,179
Total current assets	4,989,552	3,545,347
Equipment, net	182,957	244,537
Restricted cash	859,088	1,699,759
Other long-term assets	41,650	56,131
Deferred Transaction Costs	775,037
Investment in Incuron, LLC		4,268,458
Total assets	6,848,284	9,814,232
Current liabilities:
Accounts payable	950,431	1,057,743
Accrued expenses	2,025,702	1,804,456
Deferred revenue	466,590	156,317
Accrued warrant liability	5,356,391	862,074
Current portion of notes payable	2,836,723	2,640,968
Current portion of capital lease obligation		7,522
Total current liabilities	11,635,837	6,529,080
Long-term debt	$ 1,135,769	$ 1,499,050
Commitments and contingencies
Total liabilities	$ 12,771,606	$ 8,028,130
Stockholders' equity:
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2015 and 2014, respectively
Common stock, $.005 par value; 160,000,000 shares authorized, 4,269,175 and 2,858,126 shares issued and outstanding as of June 30, 2015 and 2014, respectively	$ 21,342	$ 14,287
Additional paid-in capital	134,042,180	132,693,988
Other comprehensive loss	(425,459)	(380,110)
Accumulated deficit	(142,706,512)	(133,935,562)
Treasury Stock, at cost; 264,318 and 0 shares, respectively	(906,321)
Total Cleveland BioLabs, Inc. stockholders' deficit	(9,974,770)	(1,607,397)
Noncontrolling interest in stockholders' equity	4,051,448	3,393,499
Total stockholders' equity	(5,923,322)	1,786,102
Total liabilities and stockholders' equity	$ 6,848,284	$ 9,814,232

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.005	$ 0.005
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.005	$ 0.005
Common stock, shares authorized	160,000,000	160,000,000
Common stock, shares issued	4,269,175	2,858,126
Common stock, shares outstanding	4,269,175	2,858,126
Treasury stock, Shares	264,318	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Grants and contracts	$ 329,908	$ 562,087	$ 937,237	$ 1,896,341
Operating expenses:
Research and development	1,583,169	2,324,223	3,194,139	4,763,996
General and administrative	1,597,556	2,250,368	3,905,427	4,663,911
Total operating expenses	3,180,725	4,574,591	7,099,566	9,427,907
Loss from operations	(2,850,817)	(4,012,504)	(6,162,329)	(7,531,566)
Other income (expense):
Interest and other expense	(81,416)	(623,786)	(127,810)	(941,708)
Foreign exchange gain (loss)	65,058	92,594	21,323	(59,177)
Change in value of warrant liability	(1,480,048)	412,125	(1,529,406)	2,499,683
Equity in loss of Incuron, LLC	(114,571)		(362,137)
Total other income (expense)	(1,610,977)	(119,067)	(1,998,030)	1,498,798
Net loss	(4,461,794)	(4,131,571)	(8,160,359)	(6,032,768)
Net loss attributable to noncontrolling interests	17,141	170,410	65,384	486,235
Net loss attributable to Cleveland BioLabs, Inc.	$ (4,444,653)	$ (3,961,161)	$ (8,094,975)	$ (5,546,533)
Net loss per share, basic and diluted	$ (1.12)	$ (1.53)	$ (2.25)	$ (2.18)
Weighted average number of shares, basic and diluted	3,979,783	2,594,582	3,595,153	2,546,760

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net loss including noncontrolling interests	$ (4,461,794)	$ (4,131,571)	$ (8,160,359)	$ (6,032,768)
Other comprehensive loss - Foreign currency translation adjustment	41,748	199,052	2,009	(92,414)
Comprehensive loss including noncontrolling interests	(4,420,046)	(3,932,519)	(8,158,350)	(6,125,182)
Comprehensive loss attributable to noncontrolling interests	106	90,531	63,374	507,807
Comprehensive loss attributable to Cleveland BioLabs, Inc.	$ (4,419,940)	$ (3,841,988)	$ (8,094,976)	$ (5,617,375)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interests [Member]
Beginning balance at Dec. 31, 2014	$ 1,786,102	$ 14,287		$ 132,693,988	$ (380,110)	$ (133,935,562)	$ 3,393,499
Beginning balance, Shares at Dec. 31, 2014		2,858,126
Stock based compensation	200,925	$ 25		200,900
Stock based compensation, Shares		5,023
Issuance of common stock, net of offering costs	1,154,322	$ 7,030		1,147,292
Issuance of common stock, net of offering costs, shares		1,406,026
Repurchase of Treasury Stock	(906,321)		$ (906,321)
Repurchase of Treasury Stock, Shares			264,318
Increased Ownership of Panacela Labs, Inc.					(45,348)	(675,975)	721,323
Net loss	(8,160,359)					(8,094,975)	(65,384)
Foreign currency translation	2,009				(1)		2,010
Ending balance at Jun. 30, 2015	$ (5,923,322)	$ 21,342	$ (906,321)	$ 134,042,180	$ (425,459)	$ (142,706,512)	$ 4,051,448
Ending balance, Shares at Jun. 30, 2015		4,269,175	264,318

Consolidated Statement of Stoc7

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)	6 Months Ended
	Jun. 30, 2015USD ($)
Common Stock [Member]
Offering costs	$ 98,846

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (8,160,359)	$ (6,032,768)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	126,498	686,471
Loss on equipment disposal		24,685
Noncash compensation	40,506	182,617
Warrant issuance costs	617,776	171,116
Equity in loss of Incuron, LLC	362,137
Change in value of warrant liability	1,529,406	(2,499,683)
Changes in operating assets and liabilities:
Accounts receivable and other current assets	96,807	(56,302)
Other long-term assets	8,544	15,879
Accounts payable and accrued expenses	(104,909)	(47,251)
Deferred revenue	510,743	(170,766)
Net cash used in operating activities	(4,972,851)	(7,726,002)
Cash flows from investing activities:
Purchase of short-term investments	(784,110)
Sale of short-term investments	348,452	285,881
Purchase of equipment	(13,288)	(10,803)
Divestiture of Incuron	2,000,000
Decrease in restricted cash	834,989
Net cash provided by investing activities	2,386,043	275,078
Cash flows from financing activities:
Issuance of common stock, net of offering costs	3,048,934	9,697,501
Repayment of long-term debt and capital leases	(375,972)	(4,040,329)
Noncontrolling interest capital contribution to Incuron, LLC		2,915,239
Net cash provided by financing activities	2,672,962	8,572,411
Effect of exchange rate change on cash and equivalents	(2)	(66,357)
Increase in cash and cash equivalents	86,152	1,055,130
Cash and cash equivalents at beginning of period	3,103,969	10,048,466
Cash and cash equivalents at end of period	3,190,121	11,103,596
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	$ 91,614	360,642
Supplemental schedule of noncash financing activities:
Noncash financing costs on common stock offering		50,505
Noncash warrant issuance costs		$ 15,993

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We conduct business in the United States and in the Russian Federation, or Russia, through a wholly-owned subsidiary and a consolidated joint venture owned in collaboration with a financial partner. As used throughout these unaudited consolidated financial statements, the terms “Cleveland BioLabs” and “CBLI” refer to Cleveland BioLabs, Inc. and its wholly-owned subsidiary, BioLab 612, LLC, but not its consolidated joint venture, Panacela Labs, Inc. The “Company,” “we,” “us” and “our” refer to Cleveland BioLabs, Inc. together with its consolidated subsidiaries. CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. As of June 30, 2015, the Company had one wholly-owned subsidiary, Biolab 612, LLC, or Biolab 612, which began operations in 2012, and one consolidated joint venture, Panacela Labs, Inc., or Panacela, which was formed by us and a financial partner in 2011. Panacela has a wholly-owned subsidiary, Panacela Labs, LLC, which was formed in 2011. Additionally, the Company formed a consolidated joint venture, Incuron LLC, or Incuron, with a financial partner in 2010. As of November 25, 2014, the Company no longer maintained a controlling interest in Incuron. On April 29, 2015, the Company sold 75% of its interest in Incuron, and on June 30, 2015 the Company sold its remaining interest in Incuron.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of CBLI, BioLab 612, and Panacela. The accounts of Incuron are also included through November 25, 2014, the date at which CBLI no longer maintained a controlling interest in Incuron. For the period from November 25, 2014 through April 29, 2015, the Company’s interest in Incuron is presented using the equity method of accounting, with the completed sale of our entire equity interests in Incuron recorded in the quarter ended June 30, 2015. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission, or the SEC. In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2015, along with its results of operations for the three and six month periods ended June 30, 2015 and 2014 and cash flows for the six month periods ended June 30, 2015 and 2014. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. On January 28, 2015, the Company, after receiving approval from the Company’s shareholders and board of directors, executed a reverse stock split, or Reverse Split, of the Company’s common stock at the ratio of 1:20. Unless otherwise indicated, all of the Company’s historical share balances and share price-related data have been adjusted, on a retroactive basis, to reflect this ratio. At June 30, 2015, we had cash, cash equivalents and short-term investments of $3.6 million in the aggregate. Of that amount, $1.3 million ($0.9 million of cash and cash equivalents and $0.4 million of short-term investments) was restricted for the use of our consolidated joint venture, Panacela, leaving $2.3 million available for general use. As more fully described in Note 9, Subsequent Events, the Company raised $25 million through the sale of common stock in a private placement which closed on July 9, 2015. Management believes this additional capital will fund its operations and cash requirements for at least the next 12 months. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents As of June 30, 2015, $0.9 million of the Company’s cash and cash equivalents was restricted for the use of Panacela, leaving $2.3 million available for general use. Short-Term Investments The Company’s short-term investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Accordingly, these investments are carried at amortized cost. Short-term investments classified as held-to-maturity consisted of certificates of deposit with maturity dates beyond three months and less than one year. As of June 30, 2015, all of the Company’s short-term investments were restricted for the use of Panacela. Significant Customers and Accounts Receivable Grant and contract revenue from the U.S. government accounted for 0% and 1.2% of total revenue for the three and six months ended June 30, 2014, respectively. No such revenue was reported for the three and six months ended June 30, 2015. Grant and contract revenue received by the Company’s subsidiaries from Russian government agencies accounted for 58.3% and 58.2% of total revenues for the three and six months ended June 30, 2015, respectively and 100% and 98.8% of total revenue for the three and six months ended June 30, 2014, respectively. Although the Company anticipates ongoing U.S. and Russian government contract and grant revenue, there is no guarantee that these revenue streams will continue in the future. Service contract revenue received by us from Incuron accounted for 41.7% and 41.8% of total revenues for the three and six months ended June 30, 2015, respectively. No such revenue was reported for the three and six months ended June 30, 2014. Accounts receivable consist of amounts due under reimbursement contracts with certain government and foreign entities. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within 30 days. Intellectual Property Costs related to filing and pursuing patent applications are recognized as general and administrative expenses, or G&A expenses, as incurred, since the recoverability of such expenditures is uncertain. Upon marketing approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent. Accounting for Stock-Based Compensation The 2006 Equity Incentive Plan, as amended, or the Plan, authorizes CBLI to grant (i) options to purchase common stock, (ii)restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of June 30, 2015 and taking into consideration the increase in authorized shares under the Plan as approved by our shareholders in April 2015, an aggregate of 650,000 shares of common stock were authorized for issuance under the Plan, of which a total of 158,585 shares of common stock remained available for future awards. A single participant cannot be awarded more than 100,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company’s board of directors, compensation committee or its management delegates. In June 2013, the Company’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of common stock. As of June 30, 2015, and taking into consideration the increase in authorized shares under the ESPP as approved by our shareholders in April 2015, there are 225,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of: (i) 10% of the total number of shares of common stock outstanding on December 31st of the preceding year, or (ii) 100,000 shares of common stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of common stock at an amount equal to 85% of the fair market value of the Company’s common stock on the offering date or the purchase date, whichever is less. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used: For the six months ended June 30, 2015 2014 Risk-free interest rate 1.35 - 1.59 % 1.59 - 1.98 % Expected dividend yield 0.00 % 0 % Expected life 5 - 5.5 Years 5 - 6 Years Expected volatility 76.66 - 116.10 % 71.24 - 77.99 % “Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted. “Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. “Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted. “Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history. Income Taxes No income tax expense was recorded for the three and six months ended June 30, 2015 and 2014, as the Company does not expect to have taxable income for 2015 and did not have taxable income in 2014. A full valuation allowance has been recorded against the Company’s deferred tax asset. Earnings (Loss) per Share Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of June 30, Common Equivalent Securities 2015 2014 Warrants 2,272,523 1,030,711 Options 365,784 311,206 Total 2,638,307 1,341,917 Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation that was estimable and had a probability of loss.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments The Company measures and records warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, includes: Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets; Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use. The following tables represent the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis: As of June 30, 2015 Level 1 Level 2 Level 3 Total Liabilities: Accrued warrant liability $ — $ — $ 5,356,391 $ 5,356,391 Total liabilities $ — $ — $ 5,356,391 $ 5,356,391 As of December 31, 2014 Level 1 Level 2 Level 3 Total Liabilities: Accrued warrant liability $ — $ — $ 862,074 $ 862,074 Compensatory stock options not yet issued (1) — — 132,295 132,295 Total liabilities $ — $ — $ 994,369 $ 994,369 (1) Included in accrued expenses in the accompanying Consolidated Balance Sheets The Company uses the Black-Scholes model to measure the accrued warrant liability and its accrual for compensatory stock options not yet issued. The following are the assumptions used to measure the accrued warrant liability which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2: June 30, 2015 December 31, 2014 Stock Price $ 4.34 $ 5.60 Exercise Price $ 3.00 - 100.00 $ 10.10 - 100.00 Term in years 0.04 - 6.10 0.46 - 6.04 Volatility 83.99 - 327.4 % 70.69 - 100.08 % Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield .01 - 1.87 % .12 - 1.65 % The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the periods indicated: Three Months Ended June 30, 2015 Six Months Ended June 31, 2015 Accrued Warrant Compensatory Year End Accrued Compensatory Year End Beginning Balance $ 4,547,691 $ 132,295 $ 862,074 $ 132,295 Total (gains) or losses, realized and unrealized, included in earnings (1)(2) 1,480,049 (26,381 ) 1,529,406 (26,381 ) Issuances — — 3,636,260 — Settlements (671,349 ) (105,914 ) (671,349 ) (105,914 ) Balance, June 30, 2015 $ 5,356,391 $ — $ 5,356,391 $ — Three Months Ended June 30, 2014 Six Months Ended June 30, 2014 Accrued Warrant Compensatory Year End Accrued Compensatory Beginning Balance $ 1,436,845 $ — $ 1,241,311 $ 309,450 Total (gains) or losses, realized and unrealized, included in earnings (1)(2) (412,125 ) — (2,499,683 ) (21,055 ) Issuances — — 2,283,092 — Settlements — — — (288,395 ) Balance, June 30, 2014 $ 1,024,720 $ — $ 1,024,720 $ — (1) Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no realized gains or losses for the three and six months ended June 30, 2015 and 2014. (2) Expenses recorded for compensatory stock options not yet issued are included in research & development expense and general and administrative expense. As of June 30, 2015 and December 31, 2014, the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis. The Company considers the accrued warrant liability and compensatory stock options not yet issued to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. Both the accrued warrant liability and compensatory stock options not yet issued use management’s estimate for the expected term. Additionally, the number of compensatory options awarded involves an estimate of management’s performance in relation to the targets set forth in the Company’s Executive Compensation Plan. The following table summarizes the unobservable inputs into the fair value measurement for the accrued warrant liability as of June 30, 2015: June 30, 2015 Description Fair Value Valuation Technique Unobservable Range in Accrued warrant liability 5,356,391 Black-scholes pricing model Expected term 0.04 - 6.10 $ 5,356,391 Management believes the value of both the accrued warrant liability and compensatory stock options is more sensitive to a change in the Company’s stock price at the end of the respective reporting period as opposed to a change in one of the unobservable inputs described above. The carrying amounts of the Company’s short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Sale of Incuron

Sale of Incuron	6 Months Ended
	Jun. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]
Sale of Incuron	4. Sale of Incuron On April 29, 2015, CBLI entered into an agreement to sell its equity stake in Incuron to Dr. Mikhail Mogutov, Chairman of Incuron’s Board of Directors and founder of Bioprocess Capital Ventures and/or his designee. The transaction was split into two tranches, with 75% of the Company’s equity stake in Incuron being sold for approximately $3 million on April 29, 2015, and an option being given to Dr. Mogutov to purchase CBLI’s remaining ownership interest in Incuron for approximately $1 million, which was exercised by his affiliate, BioProcess Capital Ventures, on June 30, 2015. The purchase price was paid in the form of (i) $2 million in cash received in April 2015, (ii) the transfer of 264,318 shares of the Company’s common stock to escrow with instructions to either return the shares to CBLI or pay the proceeds from the sale of such shares to CBLI, and (iii) $1 million in cash paid in July 2015. Consequently, the June 30, 2015 consolidated balance sheet presents a $1 million receivable, and has classified the cost basis of $906,321, that resulted from an independent valuation reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, as a reduction in equity in the form of treasury stock. At June 30, 2015, the governing agreement related to the 264,318 shares of the Company’s common stock provides the Company with an option to either have the shares returned to the treasury or sold. In addition, CBLI assigned its remaining intellectual property relating to Curaxin CBL0137 to Incuron in exchange for a 2% royalty on the future commercialization, licensing or sale of the Curaxin CBL0137 technology.

Debt

Debt	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt	5. Debt On September 30, 2013, CBLI and BioLab 612 entered into a Loan and Security Agreement, or the Loan Agreement, with Hercules Technology II, L.P., or Hercules, pursuant to which we issued a $6.0 million note and received net proceeds of $5.9 million. The loan bears interest at the greater of (i) 10.45% per annum or (ii) 10.45% plus the prevailing prime rate minus 4.25%. The loan matures on January 1, 2017, and requires interest-only payments for the initial 12 months and principal and interest payments in 27 monthly installments thereafter. In June 2014, CBLI repaid $4.0 million of the loan using net proceeds from a sale of equity and other cash. In connection with the Loan Agreement, CBLI granted a first priority lien in substantially all of CBLI’s assets (exclusive of intellectual property) to Hercules. The Loan Agreement also contains representations and warranties by CBLI and Hercules, indemnification provisions in favor of Hercules, customary covenants (including limitations on other indebtedness, liens, acquisitions, investments and dividends, but excluding any financial covenants), and events of default (including payment defaults, breaches of covenants, material adverse events and events leading to bankruptcy or insolvency). Prepayment of the loan is subject to a penalty rate applied to the balance of the secured obligation and ranges from 1% to 3% based on the date the loan is prepaid. The prepayment penalty was waived in connection with the above referenced prepayment in June 2014. Additional loan features, all of which are recorded debt issuance costs and loan discounts in non-current assets, include: $102,000 related to legal fees and a $100,000 facility fee both of which were paid in cash, a $550,000 “end-of-term charge” which is due upon full repayment of the loan or on the maturity date, whichever occurs sooner and is included in long-term liabilities, and a five-year warrant to purchase 7,813 shares of CBLI common stock. The warrant had an initial exercise price of $32.00 per share, which was subsequently lowered to $10.10 per share in accordance with its terms. The Black-Scholes pricing model yielded $117,999 as the fair value of the warrant upon issuance which was recorded as equity. CBLI will amortize the loan discounts and debt issuance costs to interest expense over the term of the loan using the effective interest rate method, which approximates 16.6%. The following schedule shows the remaining payments for principal and the end of term charge on the Hercules loan by calendar year: June 30, 2016 $ 788,877 2017 1,279,220 Total $ 2,068,097 On September 3, 2013, Panacela entered into a Master Agreement and a Convertible Loan Agreement, with Open Joint Stock Company RUSNANO, or Rusnano, and CBLI pursuant to which Panacela issued a $1,530,000 note to Rusnano, or the Panacela Loan. The Panacela Loan bears interest at a rate of 16.3% per annum and matures on September 10, 2015, at which time Panacela must repay all unpaid principal and accrued interest. As of June 30, 2015, Panacela had $510,977 of interest accrued associated with the Panacela Loan. Rusnano has the option to convert the unpaid principal plus interest into shares of Panacela preferred stock at a conversion price of $1,057 per share, or if Panacela has a qualified financing event, at a discounted price of 0.75 times the purchase price per share.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders' Equity	6. Stockholders’ Equity On February 4, 2015, CBLI entered into a Securities Purchase Agreement with certain institutional investors providing for the issuance and sale of 572,205 registered shares, or the Shares, of the Company’s common stock, at an offering price of $3.00 per share, or the Share Offering, and Series B pre-funded warrants, or the Pre-Funded Warrants, to purchase an aggregate of 594,688 registered shares of its common stock, or the Pre-Funded Warrants Offering. The Share Offering and the Pre-Funded Warrants Offering are referred to collectively as the Offerings. In a concurrent private placement, or the Private Placement Transaction, and, together with the Offerings, CBLI sold to the purchasers of our Shares and Pre-Funded Warrants, 717.4 shares of our Series A Convertible Preferred Stock, stated value of $1,000 per share, or the Preferred Stock, which are convertible into 239,134 shares of our common stock. Gross proceeds from the Offerings amounted to approximately $4.2 million before deducting placement agent fees and expenses. In addition, Series A warrants, or the Series A Warrants, were issued to purchase one share of our common stock for each share of common stock purchased or prefunded in the Offerings and each share of Series A Convertible Preferred Stock purchased in the Private Placement Transaction. The Series A Warrants cover, in the aggregate, 1,406,028 shares of common stock and become exercisable six months following the date of issuance at an exercise price of $3.64 and expire six years from the date they become exercisable. The Series A Warrants and Series B Warrants contain provisions that could require CBLI to settle the warrants in cash, and also provide for price or share issuance adjustments in the event of a subsequent qualified issuance of common stock at a price below $3.64 for the Series A Warrants or $3.00 for the Pre-Funded Warrants, and accordingly have been classified as a liability. As of February 6, 2015, the closing date, the fair value of the Preferred Stock and the Pre-Funded Warrants amounted to $3,636,260 and was determined based on the following assumptions using the Black-Scholes valuation model: Series A Series B Stock Price $ 3.16 $ 3.16 Exercise Price $ 3.64 $ 3.00 Term in years 6.50 1.00 Volatility 0.83 % 0.88 % Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield 1.48 % 0.26 % As of June 30, 2014, the Pre-Funded Warrants and the Preferred Stock had fully converted into common stock and as such, no balances other than stockholders’ equity remain for these securities. The Company has granted options to purchase shares of common stock. The following is a summary of option award activity during the six months ended June 30, 2015: Six Months Ended June 30, 2015 Total Stock Weighted Average Nonvested Weighted Average December 31, 2014 261,389 $ 67.89 21,287 $ 22.34 Granted 131,500 3.19 90,750 2.58 Vested — — (842 ) 19.88 Exercised — — — — Forfeited, Canceled (27,105 ) 10.47 (18,750 ) 3.63 June 30, 2015 365,784 $ 48.89 92,445 $ 6.76 The following is a summary of outstanding stock options as of June 30, 2015: As of June 30, 2015 Stock Options Vested Stock Quantity 365,784 273,339 Weighted-average exercise price $ 48.89 $ 62.51 Weighted Average Remaining Contractual Term (in Years) 7.11 6.33 Intrinsic value $ — $ — For the six months ended June 30, 2015 and 2014, the Company granted 131,500 and 49,550 stock options, respectively, with a weighted-average grant date fair value of $2.59 and $7.60, respectively. For the six months ended June 30, 2015 and 2014, the total fair value of options vested was $105,914 and $200,658, respectively. As of June 30, 2015, total compensation cost not yet recognized related to unvested stock options was $164,425. The Company expects to recognize this cost over a weighted average period of approximately 0.45 years.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants	7. Warrants In connection with sales of the Company’s common stock and the issuance of debt instruments, warrants were issued which presently have exercise prices ranging from $3.00 to $100.00. The warrants expire between one and seven years from the date of grant, and are subject to the terms applicable in each agreement. The following table summarizes the activity in our outstanding warrants since December 31, 2014: Number of Weighted Average Warrants Exercise Price Outstanding at December 31, 2014 875,304 $ 33.72 Granted 1,406,028 3.64 Forfeited, Canceled (8,809 ) 100.00 Outstanding at June 30, 2015 2,272,523 14.16 In addition, the Company has issued a warrant to Rusnano, our financial partner in Panacela, or the Rusnano Warrant, that can only be exercised in the event Panacela defaults on a loan from Rusnano, or the Rusnano Loan. The maximum number of shares issuable under the Rusnano Warrant as of June 30, 2015 is 41,706. At June 30, 2015, Panacela was not in default of the Rusnano Loan.

Significant Alliances and Relat

Significant Alliances and Related Parties	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Significant Alliances and Related Parties	8. Significant Alliances and Related Parties Roswell Park Cancer Institute The Company has entered into several agreements with Roswell Park Cancer Institute, or RPCI, including: various sponsored research agreements, an exclusive license agreement and clinical trial agreements for the conduct of the Phase 1 entolimod oncology study and the Phase 1 CBL0137 intravenous administration study. Additionally, the Company’s Chief Scientific Officer, or CSO, Dr. Andrei Gudkov, is the Senior Vice President of Basic Research at RPCI. The Company incurred $264,693 and $469,371 in expense to RPCI related to research grants and agreements for the quarters ended June 30, 2015 and 2014, respectively. The Company had $381,837 and $210,882 included in accounts payable owed to RPCI at June 30, 2015 and 2014, respectively. In addition, the Company had $157,110 and $210,882 in accrued expenses payable to RPCI at June 30, 2015 and 2014, respectively. The Cleveland Clinic CBLI entered into an exclusive license agreement, or the License, with The Cleveland Clinic pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic’s research base underlying our therapeutic platform and certain product candidates licensed to Panacela. CBLI has the primary responsibility to fund all newly developed patents; however, The Cleveland Clinic retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring one or more products to market as soon as practical, consistent with sound and reasonable business practices and judgments. There were no milestone or royalty payments paid to CCF during the six months ended June 30, 2015 or 2014. The Company did not have any liabilities to The Cleveland Clinic at June 30, 2015 or 2014. Buffalo BioLabs, et. al. Our CSO, Dr. Andrei Gudkov has business relationships with several entities with which we transact business, the most significant of which is Buffalo BioLabs, LLC, or BBL, where Dr. Gudkov was a founder and currently serves as their Principal Scientific Advisor. Such description of services is more thoroughly discussed in Note 8, Restructuring, of our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on February 27, 2015. The Company recognized $245,417 and $359,823 as research and development expense for the quarters ended June 30, 2015 and 2014, respectively, and included $0 and $9,836 in accounts payable to BBL at June 30, 2015 and 2014. In addition, the Company had $0 and $66,077 in accrued expenses payable to BBL at June 30, 2015 and 2014, respectively. We also recognized $55,962 and $87,490 from BBL for sublease and other income for the quarters ended June 30, 2015 and 2014, respectively. Pursuant to our real estate sublease and equipment lease with BBL, we had gross and net accounts receivable of $227,086, and 0 at June 30, 2015, respectively and a gross receivable of $67,915 at June 30, 2014.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events On July 9, 2015, the Company sold 6,459,948 shares of the Company’s common stock to David Davidovich, a venture capital, accredited investor, for $25 million, or $3.87 per share, the “July Equity Investment.” Additionally, the Company has elected to prepay the remaining obligations due under its loan with Hercules, the “Hercules Prepayment.” Considering therefore the subsequent receipt of approximately $23.5 million in net proceeds from the July Equity Investment, the subsequent receipt of $1.0 million from the sale of the Company’s remaining equity interest in Incuron as further described in Note 4, Sale of Incuron, and approximately $2.0 million subsequently disbursed for the Hercules Prepayment, the Company had approximately $26.1 million in cash, cash equivalents and short-term investments on a pro-forma basis as of June 30, 2015. As a result of the foregoing and other changes occurring in the normal course of the Company’s business since June 30, 2015, 10,729,123 shares of the Company’s common stock are currently issued and outstanding, along with 2,227,232 warrants that have a weighted average exercise price of $13.95 per share, exclusive of the Rusnano Warrant described in Note 7, Warrants, and 365,784 options with a weighted average exercise price of $48.89. Additionally, as disclosed in Note 10, Income Taxes, of the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2014 and filed with the SEC on February 27, 2015, the Company had U.S. federal net operating loss carryforwards of approximately $120,934,000, which begin to expire if not utilized by 2023, and approximately $3,565,000 of federal tax credit carryforwards which begin to expire if not utilized by 2024. The Company also has U.S. state net operating loss carryforwards of approximately $110,957,000, which begin to expire if not utilized by 2027 and state tax credit carryforwards of approximately $337,000, which begin to expire if not utilized by 2022. The purchase of 6,459,948 shares of common stock by Mr. Davidovich yields a post-transaction ownership percentage of 60.2% for him. We believe it highly likely that this transaction will be viewed by the U.S. Internal Revenue Service as a change of ownership as defined by Section 382 of the Internal Revenue Code (“Section 382”). Consequently, the utilization of these net operating loss and tax credit carryforwards, as well as any additional net operating loss and tax credit carryforwards generated in 2015 through the issuance date, will be limited according to the provisions of Section 382, which will significantly limit the Company’s ability to use these carryforwards to offset taxable income on an annual basis in future periods. As such a significant portion of these carryforwards will likely expire before they can be utilized, even if the Company is able to generate taxable income that, except for this transaction, would have been sufficient to fully utilize these carryforwards.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of CBLI, BioLab 612, and Panacela. The accounts of Incuron are also included through November 25, 2014, the date at which CBLI no longer maintained a controlling interest in Incuron. For the period from November 25, 2014 through April 29, 2015, the Company’s interest in Incuron is presented using the equity method of accounting, with the completed sale of our entire equity interests in Incuron recorded in the quarter ended June 30, 2015. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission, or the SEC. In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2015, along with its results of operations for the three and six month periods ended June 30, 2015 and 2014 and cash flows for the six month periods ended June 30, 2015 and 2014. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. On January 28, 2015, the Company, after receiving approval from the Company’s shareholders and board of directors, executed a reverse stock split, or Reverse Split, of the Company’s common stock at the ratio of 1:20. Unless otherwise indicated, all of the Company’s historical share balances and share price-related data have been adjusted, on a retroactive basis, to reflect this ratio. At June 30, 2015, we had cash, cash equivalents and short-term investments of $3.6 million in the aggregate. Of that amount, $1.3 million ($0.9 million of cash and cash equivalents and $0.4 million of short-term investments) was restricted for the use of our consolidated joint venture, Panacela, leaving $2.3 million available for general use. As more fully described in Note 9, Subsequent Events, the Company raised $25 million through the sale of common stock in a private placement which closed on July 9, 2015. Management believes this additional capital will fund its operations and cash requirements for at least the next 12 months.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents As of June 30, 2015, $0.9 million of the Company’s cash and cash equivalents was restricted for the use of Panacela, leaving $2.3 million available for general use.
Short-Term Investments	Short-Term Investments The Company’s short-term investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Accordingly, these investments are carried at amortized cost. Short-term investments classified as held-to-maturity consisted of certificates of deposit with maturity dates beyond three months and less than one year. As of June 30, 2015, all of the Company’s short-term investments were restricted for the use of Panacela.
Significant Customers and Accounts Receivable	Significant Customers and Accounts Receivable Grant and contract revenue from the U.S. government accounted for 0% and 1.2% of total revenue for the three and six months ended June 30, 2014, respectively. No such revenue was reported for the three and six months ended June 30, 2015. Grant and contract revenue received by the Company’s subsidiaries from Russian government agencies accounted for 58.3% and 58.2% of total revenues for the three and six months ended June 30, 2015, respectively and 100% and 98.8% of total revenue for the three and six months ended June 30, 2014, respectively. Although the Company anticipates ongoing U.S. and Russian government contract and grant revenue, there is no guarantee that these revenue streams will continue in the future. Service contract revenue received by us from Incuron accounted for 41.7% and 41.8% of total revenues for the three and six months ended June 30, 2015, respectively. No such revenue was reported for the three and six months ended June 30, 2014. Accounts receivable consist of amounts due under reimbursement contracts with certain government and foreign entities. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within 30 days.
Intellectual Property	Intellectual Property Costs related to filing and pursuing patent applications are recognized as general and administrative expenses, or G&A expenses, as incurred, since the recoverability of such expenditures is uncertain. Upon marketing approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
Accounting for Stock-Based Compensation	Accounting for Stock-Based Compensation The 2006 Equity Incentive Plan, as amended, or the Plan, authorizes CBLI to grant (i) options to purchase common stock, (ii)restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of June 30, 2015 and taking into consideration the increase in authorized shares under the Plan as approved by our shareholders in April 2015, an aggregate of 650,000 shares of common stock were authorized for issuance under the Plan, of which a total of 158,585 shares of common stock remained available for future awards. A single participant cannot be awarded more than 100,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company’s board of directors, compensation committee or its management delegates. In June 2013, the Company’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of common stock. As of June 30, 2015, and taking into consideration the increase in authorized shares under the ESPP as approved by our shareholders in April 2015, there are 225,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of: (i) 10% of the total number of shares of common stock outstanding on December 31st of the preceding year, or (ii) 100,000 shares of common stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of common stock at an amount equal to 85% of the fair market value of the Company’s common stock on the offering date or the purchase date, whichever is less. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used: For the six months ended June 30, 2015 2014 Risk-free interest rate 1.35 - 1.59 % 1.59 - 1.98 % Expected dividend yield 0.00 % 0 % Expected life 5 - 5.5 Years 5 - 6 Years Expected volatility 76.66 - 116.10 % 71.24 - 77.99 % “Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted. “Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. “Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted. “Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.
Income Taxes	Income Taxes No income tax expense was recorded for the three and six months ended June 30, 2015 and 2014, as the Company does not expect to have taxable income for 2015 and did not have taxable income in 2014. A full valuation allowance has been recorded against the Company’s deferred tax asset.
Earnings (Loss) per Share	Earnings (Loss) per Share Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of June 30, Common Equivalent Securities 2015 2014 Warrants 2,272,523 1,030,711 Options 365,784 311,206 Total 2,638,307 1,341,917
Contingencies	Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation that was estimable and had a probability of loss.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Assumptions Used in Valuing Stock Options Granted	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used: For the six months ended June 30, 2015 2014 Risk-free interest rate 1.35 - 1.59 % 1.59 - 1.98 % Expected dividend yield 0.00 % 0 % Expected life 5 - 5.5 Years 5 - 6 Years Expected volatility 76.66 - 116.10 % 71.24 - 77.99 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of June 30, Common Equivalent Securities 2015 2014 Warrants 2,272,523 1,030,711 Options 365,784 311,206 Total 2,638,307 1,341,917

Fair Value of Financial Instr20

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis	The following tables represent the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis: As of June 30, 2015 Level 1 Level 2 Level 3 Total Liabilities: Accrued warrant liability $ — $ — $ 5,356,391 $ 5,356,391 Total liabilities $ — $ — $ 5,356,391 $ 5,356,391 As of December 31, 2014 Level 1 Level 2 Level 3 Total Liabilities: Accrued warrant liability $ — $ — $ 862,074 $ 862,074 Compensatory stock options not yet issued (1) — — 132,295 132,295 Total liabilities $ — $ — $ 994,369 $ 994,369 (1) Included in accrued expenses in the accompanying Consolidated Balance Sheets
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions	The following are the assumptions used to measure the accrued warrant liability which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2: June 30, 2015 December 31, 2014 Stock Price $ 4.34 $ 5.60 Exercise Price $ 3.00 - 100.00 $ 10.10 - 100.00 Term in years 0.04 - 6.10 0.46 - 6.04 Volatility 83.99 - 327.4 % 70.69 - 100.08 % Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield .01 - 1.87 % .12 - 1.65 %
Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the periods indicated: Three Months Ended June 30, 2015 Six Months Ended June 31, 2015 Accrued Warrant Compensatory Year End Accrued Compensatory Year End Beginning Balance $ 4,547,691 $ 132,295 $ 862,074 $ 132,295 Total (gains) or losses, realized and unrealized, included in earnings (1)(2) 1,480,049 (26,381 ) 1,529,406 (26,381 ) Issuances — — 3,636,260 — Settlements (671,349 ) (105,914 ) (671,349 ) (105,914 ) Balance, June 30, 2015 $ 5,356,391 $ — $ 5,356,391 $ — Three Months Ended June 30, 2014 Six Months Ended June 30, 2014 Accrued Warrant Compensatory Year End Accrued Compensatory Beginning Balance $ 1,436,845 $ — $ 1,241,311 $ 309,450 Total (gains) or losses, realized and unrealized, included in earnings (1)(2) (412,125 ) — (2,499,683 ) (21,055 ) Issuances — — 2,283,092 — Settlements — — — (288,395 ) Balance, June 30, 2014 $ 1,024,720 $ — $ 1,024,720 $ — (1) Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no realized gains or losses for the three and six months ended June 30, 2015 and 2014. (2) Expenses recorded for compensatory stock options not yet issued are included in research & development expense and general and administrative expense.
Summary of Unobservable Inputs in Fair Value Measurements	The following table summarizes the unobservable inputs into the fair value measurement for the accrued warrant liability as of June 30, 2015: June 30, 2015 Description Fair Value Valuation Technique Unobservable Range in Accrued warrant liability 5,356,391 Black-scholes pricing model Expected term 0.04 - 6.10 $ 5,356,391

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Summary of Principal Payments	The following schedule shows the remaining payments for principal and the end of term charge on the Hercules loan by calendar year: June 30, 2016 $ 788,877 2017 1,279,220 Total $ 2,068,097

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2015
Summary of Option Award Activity	The following is a summary of option award activity during the six months ended June 30, 2015: Six Months Ended June 30, 2015 Total Stock Weighted Average Nonvested Weighted Average December 31, 2014 261,389 $ 67.89 21,287 $ 22.34 Granted 131,500 3.19 90,750 2.58 Vested — — (842 ) 19.88 Exercised — — — — Forfeited, Canceled (27,105 ) 10.47 (18,750 ) 3.63 June 30, 2015 365,784 $ 48.89 92,445 $ 6.76
Summary of Outstanding Stock Options	The following is a summary of outstanding stock options as of June 30, 2015: As of June 30, 2015 Stock Options Vested Stock Quantity 365,784 273,339 Weighted-average exercise price $ 48.89 $ 62.51 Weighted Average Remaining Contractual Term (in Years) 7.11 6.33 Intrinsic value $ — $ —
Pre-Funded Warrants [Member]
Summary of Assumptions Used in Valuing Stock Options Granted	The fair value of the Preferred Stock and the Pre-Funded Warrants amounted to $3,636,260 and was determined based on the following assumptions using the Black-Scholes valuation model: Series A Series B Stock Price $ 3.16 $ 3.16 Exercise Price $ 3.64 $ 3.00 Term in years 6.50 1.00 Volatility 0.83 % 0.88 % Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield 1.48 % 0.26 %

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Warrants Outstanding	The following table summarizes the activity in our outstanding warrants since December 31, 2014: Number of Weighted Average Warrants Exercise Price Outstanding at December 31, 2014 875,304 $ 33.72 Granted 1,406,028 3.64 Forfeited, Canceled (8,809 ) 100.00 Outstanding at June 30, 2015 2,272,523 14.16

Description of Business - Addit

Description of Business - Additional Information (Detail) - Subsidiary	Apr. 29, 2015	Jun. 30, 2015
BioLab 612 [Member]
Subsidiary or Equity Method Investee [Line Items]
Number Of wholly-owned subsidiaries		1
Panacela [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of majority owned subsidiaries		1
Incuron, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Percentage of equity stake sold	75.00%

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Additional Information (Detail)	Jul. 09, 2015USD ($)	Jan. 28, 2015	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)
Accounting Policies [Line Items]
Reverse stock split ratio		0.20
Cash and cash equivalents and short-term investments			$ 3,640,377		$ 3,640,377
Restricted cash and cash equivalents and short-term investments			1,300,000		1,300,000
Restricted cash and cash equivalents			900,000		900,000
Restricted short-term investments			400,000		400,000
General use cash total			$ 2,300,000		$ 2,300,000
Share-based compensation arrangement by share-based payment award, number of shares authorized | shares			650,000		650,000
Share-based compensation arrangement by share-based payment award, number of shares available for grant | shares			158,585		158,585
Share-based compensation arrangement by share-based payment award number of shares limited per year | shares					100,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, outstanding, weighted average remaining contractual terms					10 years
Income tax expense			$ 0	$ 0	$ 0	$ 0
2013 ESPP Plan [Member]
Accounting Policies [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant | shares			225,000		225,000
Percentage of the total number of shares of common stock outstanding of the preceding year					10.00%
Share-based compensation arrangement by share-based payment award, number of shares limited per year | shares			100,000		100,000
Share-based compensation arrangement by share-based payment award, maximum employee subscription rate			15.00%		15.00%
Share-based compensation arrangement by share-based payment award, discount from market price, offering rate					85.00%
Accounts Receivable [Member]
Accounting Policies [Line Items]
Credit term					30 days
UNITED STATES | Government Contracts Concentration Risk [Member] | Sales Revenue, Services, Net [Member]
Accounting Policies [Line Items]
Concentration risk percentage			0.00%	0.00%	0.00%	1.20%
RUSSIAN FEDERATION | Government Contracts Concentration Risk [Member] | Sales Revenue, Services, Net [Member]
Accounting Policies [Line Items]
Concentration risk percentage			58.30%	100.00%	58.20%	98.80%
Subsequent Event [Member]
Accounting Policies [Line Items]
Cash proceeds from sale of equity stake	$ 25,000,000
Minimum [Member] | Certificates of Deposit [Member]
Accounting Policies [Line Items]
Short-term investments maturity					3 months
Panacela [Member]
Accounting Policies [Line Items]
Restricted cash and cash equivalents			$ 900,000		$ 900,000
Incuron, LLC [Member] | Customer Concentration Risk [Member] | Sales Revenue, Services, Net [Member]
Accounting Policies [Line Items]
Concentration risk percentage			41.70%	0.00%	41.80%	0.00%
Incuron, LLC [Member] | Subsequent Event [Member]
Accounting Policies [Line Items]
Cash proceeds from sale of equity stake	$ 1,000,000

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Summary of Assumptions Used in Valuing Stock Options Granted (Detail)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%		0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.01%		0.12%
Expected life	15 days		5 months 16 days
Expected volatility	83.99%		70.69%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.87%		1.65%
Expected life	6 years 1 month 6 days		6 years 15 days
Expected volatility	327.40%		100.08%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.35%	1.59%
Expected life	5 years	5 years
Expected volatility	76.66%	71.24%
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.59%	1.98%
Expected life	5 years 6 months	6 years
Expected volatility	116.10%	77.99%

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,638,307	1,341,917
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,272,523	1,030,711
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	365,784	311,206

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Liabilities:
Accrued warrant liability	$ 5,356,391	$ 862,074
Compensatory stock options not yet issued		132,295
Total liabilities	5,356,391	994,369
Level 3 [Member]
Liabilities:
Accrued warrant liability	5,356,391	862,074
Compensatory stock options not yet issued		132,295
Total liabilities	$ 5,356,391	$ 994,369

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock Price	$ 4.34	$ 5.60
Annual rate of quarterly dividends	0.00%	0.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise Price	$ 3	$ 10.10
Term in years	15 days	5 months 16 days
Volatility	83.99%	70.69%
Discount rate-bond equivalent yield	0.01%	0.12%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise Price	$ 100	$ 100
Term in years	6 years 1 month 6 days	6 years 15 days
Volatility	327.40%	100.08%
Discount rate-bond equivalent yield	1.87%	1.65%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Ending balance	$ 5,356,391		$ 5,356,391
Accrued Warrant Liability [Member]
Beginning balance	4,547,691	$ 1,436,845	862,074	$ 1,241,311
Total (gains) or losses, realized and unrealized, included in earnings	1,480,049	(412,125)	1,529,406	(2,499,683)
Issuances			3,636,260	2,283,092
Settlements	(671,349)		(671,349)
Ending balance	5,356,391	$ 1,024,720	5,356,391	1,024,720
Compensatory Stock Options Not Yet Issued [Member]
Beginning balance	132,295		132,295	309,450
Total (gains) or losses, realized and unrealized, included in earnings	(26,381)		(26,381)	(21,055)
Settlements	$ (105,914)		$ (105,914)	$ (288,395)

Fair Value Measurements - Sum31

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Parenthetical) (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Series B Warrants [Member]
Realized gains or losses	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument Fair Value Carrying Value [Abstract]
Assets or liabilities	$ 0	$ 0

Fair Value Measurements - Sum33

Fair Value Measurements - Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value	$ 5,356,391
Accrued Warrant Liability [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value	$ 5,356,391	$ 4,547,691	$ 862,074	$ 1,024,720	$ 1,436,845	$ 1,241,311
Valuation Technique	Black-scholes pricing model
Unobservable Input	Expected term
Minimum [Member] | Accrued Warrant Liability [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	15 days
Maximum [Member] | Accrued Warrant Liability [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	6 years 1 month 6 days

Sale of Incuron - Additional In

Sale of Incuron - Additional Information (Detail) - USD ($)	Jul. 30, 2015	Jul. 09, 2015	Apr. 29, 2015	Jun. 30, 2015
Schedule of Equity Method Investments [Line Items]
Receivable for divestiture of Incuron, LLC				$ 1,000,000
Treasury stock, value				$ 906,321
Percentage of royalty exchanged				2.00%
Bioprocess Capital Ventures [Member]
Schedule of Equity Method Investments [Line Items]
Percentage of equity stake sold			75.00%
Cash proceeds from sale of equity stake			$ 3,000,000
Cash required to purchase remaining equity stake			1,000,000
Cash received from sale of equity stake			$ 2,000,000
Receivable for divestiture of Incuron, LLC				$ 1,000,000
Treasury stock, value				$ 906,321
Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Cash proceeds from sale of equity stake		$ 25,000,000
Subsequent Event [Member] | Bioprocess Capital Ventures [Member]
Schedule of Equity Method Investments [Line Items]
Common stock held in treasury	264,318
Payments made to joint venture	$ 1,000,000

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Sep. 30, 2013	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Exercise price per share under class of warrants or rights			$ 14.16	$ 33.72
Panacela Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,530,000
Debt Instrument, interest Rate, stated percentage	16.30%
Accrued Interest			$ 510,977
Debt Instrument, Convertible, Conversion Price (in Dollars per Share			$ 1,057
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 0.75
Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]
Debt instrument, Description of variable Rate Basis	Prime
Debt Instrument, Face Amount	$ 6,000,000
Proceeds from Notes Payable	$ 5,900,000
Debt Instrument, Interest Rate, Stated Percentage rate Range, Minimum	10.45%
Debt Instrument, Basis Spread on variable rate	4.25%
Net proceeds from sale of equity and cash		$ 4,000,000
Legal fees			102,000
Facility fees			100,000
End of term charge,			$ 550,000
Warrant term			5 years
Class of warrant or right, number of securities called by warrants or rights, shares			7,813
Exercise price per share under class of warrants or rights			$ 32
Fair value of warrants issued in connection with debt			$ 117,999
Debt Instrument, Interest rate, Effective Percentage			16.60%
Minimum [Member]
Debt Instrument [Line Items]
Exercise price per share under class of warrants or rights			$ 3
Minimum [Member] | Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]
Debt Instrument Penalty rate			1.00%
Maximum [Member]
Debt Instrument [Line Items]
Exercise price per share under class of warrants or rights			$ 100
Maximum [Member] | Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]
Debt Instrument Penalty rate			3.00%
Loan Interest - Only Payments [Member] | Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]
Debt Instrument, Frequency of Periodic Payment			12
Principle and Interest Payments [Member] | Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]
Debt Instrument, Frequency of Periodic Payment			27

Debt - Summary of Principal Pay

Debt - Summary of Principal Payments (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Total	$ 1,135,769	$ 1,499,050
Hercules Technology II, L.P. and Rusnano [Member] | Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]
2,016	788,877
2,017	1,279,220
Total	$ 2,068,097

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Feb. 06, 2015	Feb. 04, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sales of common stock , shares		572,205	4,269,175		2,858,126
Common stock, offering price per share			$ 4.34		$ 5.60
Preferred stock, shares outstanding			0		0
Preferred stock, stated value
Number of convertible preferred stock converted into common shares		239,134
Gross proceeds from issuance and sale of equity		$ 4,200,000
Exercise price per share under class of warrants or rights			$ 14.16		$ 33.72
Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures			131,500	49,550
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted-average grant date fair value			$ 2.59	$ 7.60
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value			$ 105,914	$ 200,658
Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized			$ 164,425
Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized, period for recognition			5 months 12 days
Accrued Warrant Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants			$ 3,636,260	$ 2,283,092
Preferred Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares outstanding		717.4
Preferred stock, stated value		$ 1,000
Series B Pre-funded Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sales of common stock , shares		594,688
Common stock, offering price per share		$ 3
Preferred Stock Warrant [Member] | Accrued Warrant Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants	$ 3,636,260
Pre-Funded Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3
Pre-Funded Warrants [Member] | Accrued Warrant Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants	$ 3,636,260
Series A Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant expiration term		6 years
Warrants issued		1,406,028
Exercise price per share under class of warrants or rights		$ 3.64
Exercise Price	$ 3.64

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Assumptions Used in Valuing Stock Options Granted (Detail) - $ / shares	Feb. 06, 2015	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price		$ 4.34	$ 5.60
Annual rate of quarterly dividends		0.00%	0.00%
Series A Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3.64
Black Scholes Stock Price Valuation Model [Member] | Series A Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price	3.16
Exercise Price	$ 3.64
Term in years	6 years 6 months
Volatility	0.83%
Annual rate of quarterly dividends	0.00%
Discount rate- bond equivalent yield	1.48%
Black Scholes Stock Price Valuation Model [Member] | Series B Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price	$ 3.16
Exercise Price	$ 3
Term in years	1 year
Volatility	0.88%
Annual rate of quarterly dividends	0.00%
Discount rate- bond equivalent yield	0.26%

Stockholders' Equity - Summar39

Stockholders' Equity - Summary of Option Award Activity (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Equity [Abstract]
Total Stock Options Outstanding, Beginning balance	261,389
Total Stock Options Outstanding, Granted	131,500	49,550
Total Stock Options Outstanding, Vested	0
Total Stock Options Outstanding, Exercised	0
Total Stock Options Outstanding, Forfeited, Canceled	(27,105)
Total Stock Options Outstanding, Ending balance	365,784
Weighted Average Exercise Price per Share, Beginning balance	$ 67.89
Weighted Average Exercise Price per Share, Granted	3.19
Weighted Average Exercise Price per Share, Vested	0
Weighted Average Exercise Price per Share, Exercised	0
Weighted Average Exercise Price per Share, Forfeited, Canceled	10.47
Weighted Average Exercise Price per Share, Ending balance	$ 48.89
Nonvested Stock Options, Beginning balance	21,287
Nonvested Stock Options, Granted	90,750
Nonvested Stock Options, Vested	(842)
Nonvested Stock Options, Exercised	0
Nonvested Stock Options, Forfeited, Canceled	(18,750)
Nonvested Stock Options, Ending balance	92,445
Weighted Average Grant Date Fair Value per Share, Beginning balance	$ 22.34
Weighted Average Grant Date Fair Value per Share, Granted	2.58
Weighted Average Grant Date Fair Value per Share, Vested	19.88
Weighted Average Grant Date Fair Value per Share, Exercised	0
Weighted Average Grant Date Fair Value per Share, Forfeited, Canceled	3.63
Weighted Average Grant Date Fair Value per Share, Ending balance	$ 6.76

Stockholders' Equity - Summar40

Stockholders' Equity - Summary of Outstanding Stock Options (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity	365,784	261,389
Stock Options Outstanding, Weighted-average exercise price	$ 48.89	$ 67.89
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity	365,784
Stock Options Outstanding, Weighted-average exercise price	$ 48.89
Stock Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	7 years 1 month 10 days
Stock Options Outstanding, Intrinsic value	$ 0
Vested Stock Options, Quantity	273,339
Vested Stock Options, Weighted-average exercise price	$ 62.51
Vested Stock Options, Weighted Average Remaining Contractual Term (in Years)	6 years 3 months 29 days
Vested Stock Options, Intrinsic value	$ 0

Warrants - Additional Informati

Warrants - Additional Information (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Exercise price per share under class of warrants or rights	$ 14.16	$ 33.72
Rusnano Warrant [Member]
Class of Warrant or Right [Line Items]
Rusnano default commitment	In addition, the Company has issued a warrant to Rusnano, our financial partner in Panacela, or the Rusnano Warrant, that can only be exercised in the event Panacela defaults on a loan from Rusnano, or the Rusnano Loan.
Maximum number of shares issuable	41,706
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price per share under class of warrants or rights	$ 3
Warrants expiration period	1 year
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price per share under class of warrants or rights	$ 100
Warrants expiration period	7 years

Warrants - Summary of Warrants

Warrants - Summary of Warrants Outstanding (Detail) - 6 months ended Jun. 30, 2015 - $ / shares	Total
Warrants and Rights Note Disclosure [Abstract]
Number of Warrants Outstanding, Beginning balance	875,304
Number of Warrants Granted	1,406,028
Number of Warrants Forfeited, Canceled	(8,809)
Number of Warrants Outstanding, Ending balance	2,272,523
Weighted Average Exercise Price Outstanding, Beginning balance	$ 33.72
Weighted Average Exercise Price Granted	3.64
Weighted Average Exercise Price Forfeited, Canceled	100
Weighted Average Exercise Price Outstanding, Ending balance	$ 14.16

Significant Alliances and Rel43

Significant Alliances and Related Parties - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Related Party Transaction [Line Items]
Research and development expense	$ 1,583,169	$ 2,324,223	$ 3,194,139	$ 4,763,996
Accounts receivable net	133,476		133,476		$ 267,199
R P C I [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	264,693	469,371
Accounts payable owed	381,837	210,882	381,837	210,882
Due to related parties, current	157,110	210,882	157,110	210,882
Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Royalty or sublicense royalty payments			0	0
Buffalo BioLabs [Member]
Related Party Transaction [Line Items]
Accounts payable owed	0	9,836	0	9,836
Due to related parties, current	0	66,077	0	66,077
Research and development expense	245,417	359,823
Accounts receivable gross	227,086	67,915	227,086	$ 67,915
Accounts receivable net	0		$ 0
Buffalo BioLabs [Member] | Other Income [Member]
Related Party Transaction [Line Items]
Revenue from related parties	$ 55,962	$ 87,490

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Jul. 09, 2015	Jun. 30, 2015	Feb. 04, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Cash and cash equivalents and short-term investments		$ 3,640,377
Stock option outstanding		365,784		261,389
Common stock, shares issued		4,269,175	572,205	2,858,126
Common stock, shares outstanding		4,269,175		2,858,126
Class of warrant		2,272,523		875,304
Exercise price per share under class of warrants or rights		$ 14.16		$ 33.72
Weighted average exercise price		$ 48.89		$ 67.89
Expire 2023 [Member]
Subsequent Event [Line Items]
Deferred tax assets, operating loss carryforwards, domestic				$ 120,934,000
Expire 2027 [Member]
Subsequent Event [Line Items]
Deferred tax assets, operating loss carryforwards, state and local				110,957,000
U.S. Federal Tax Credit Carryforwards [Member] | Expire 2024 [Member]
Subsequent Event [Line Items]
Deferred tax assets, tax credit carryforwards				3,565,000
U.S. State Tax Credit Carryforwards [Member] | Expire 2022 [Member]
Subsequent Event [Line Items]
Deferred tax assets, tax credit carryforwards				$ 337,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of company common stock	6,459,948
Cash proceeds from sale of equity stake	$ 25,000,000
Sale of stock, price per share	$ 3.87
Amount of debt disbursed	$ 2,000,000
Stock option outstanding	365,784
Common stock, shares issued	10,729,123
Common stock, shares outstanding	10,729,123
Class of warrant	2,227,232
Exercise price per share under class of warrants or rights	$ 13.95
Weighted average exercise price	$ 48.49
Subsequent Event [Member] | David Davidovich [Member]
Subsequent Event [Line Items]
Post transaction ownership yield percentage	61.00%
Subsequent Event [Member] | July Equity Investment [Member]
Subsequent Event [Line Items]
Cash proceeds from sale of equity stake	$ 23,500,000
Subsequent Event [Member] | Incuron, LLC [Member]
Subsequent Event [Line Items]
Cash proceeds from sale of equity stake	$ 1,000,000
Subsequent Event [Member] | Pro Forma [Member]
Subsequent Event [Line Items]
Cash and cash equivalents and short-term investments		$ 26,100,000